Shareholder Rebellion Intensifies as Staar Surgical Acquisition Reaches Critical Juncture

The proposed acquisition of Staar Surgical by Alcon is approaching a decisive moment, marked by growing dissent from major shareholders. A 45-day “go-shop” period, which concluded on Friday without a superior offer, has failed to quell the opposition. The company’s board continues to champion the deal as value-maximizing, but it now faces significant resistance from two key investors who argue the terms significantly undervalue the company.

Major Investors Challenge the Terms

The rebellion gained substantial momentum with the formal opposition of Yunqi Capital, an investment firm holding a 5.1% stake. They have aligned with the largest shareholder, Broadwood Partners, which controls 27.4% of the company. Both entities have publicly rejected Alcon’s offer of $28 per share, deeming it an inadequate valuation of Staar Surgical’s worth. Despite the unsuccessful search for an alternative bidder during the go-shop window, the atmosphere remains highly charged. Yunqi Capital has declared its intention to vote against the transaction unless the conditions are improved.

Board Holds Firm Amid Mounting Pressure

In response to the criticism, the board of Staar Surgical has reaffirmed its unanimous support for the deal. In a recent communication, the directors maintained that the acquisition by Alcon serves the best interests of all shareholders and dismissed the investors’ concerns as unfounded. The board has issued a stark warning, suggesting that a collapse of the deal could lead to substantial value destruction for shareholders.

Should investors sell immediately? Or is it worth buying Staar Surgical?

The key terms of the offer are:
* Acquisition Price: $28 per share
* Total Enterprise Value: Approximately $1.5 billion
* Takeover Premium: 51% above the share price prior to the deal’s announcement

Shareholder Vote to Determine Outcome

The fate of the acquisition now rests entirely with an extraordinary general meeting scheduled for October 23rd. The weeks leading to the vote are expected to see an escalation in the power struggle between the board and the dissenting shareholders. The market’s reaction has already been reflected in analyst adjustments; firms including Stifel and Sidoti have raised their ratings to “Hold” and “Neutral,” respectively, aligning their price targets with the offer price of $28.

The central question remains whether the board can secure the necessary majority approval or if the influential rebel shareholders will succeed in forcing a renegotiation of the terms. The coming weeks will be critical in shaping the future of Staar Surgical.